A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

Inclusion Criteria Concurrent Medication: Allowed: Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or isoniazid. Patients must have: HIV infection. CD4 count 50 - 500 cells/mm3. Prior AZT use for more than 6 months OR documented intolerance to AZT with more than 6 months use of another anti-HIV therapy other than d4T or any protease inhibitor. No active opportunistic infection or visceral Kaposi's sarcoma. NOTE: Patients with hemophilia may be enrolled at discretion of investigator. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Symptomatic neuropathy. Acute hepatitis. Concurrent Medication: Excluded: Antiretrovirals other than specified in protocol. Chronic therapy for an active opportunistic infection. Immunosuppressive therapy. Prior Medication: Excluded: Any prior protease inhibitor or d4T. Any nucleoside analogs within 2 weeks prior to study entry. Investigational agents or immunomodulators within 30 days prior to study entry. Required: More than 6 months of prior AZT unless intolerant, in which case more than 6 months of another anti-HIV therapy (other than protease inhibitors or d4T).